Canagliflozin (Invokana) has been approved since November 2013 for use as monotherapy and in various combination therapies for adults with type 2 iabetes mellitus, in which diet and exercise do not lower elevated blood sugar levels adequately. The Institute for Quality and Efficiency in Health Care (IQWiG) has now developed an early benefit assessment pursuant to the Pharmaceutical Market Restructuring Act (AMNOG) to determine whether canagliflozin alone (monotherapy) or in combination with other glucose-lowering agents offers an additional benefit compared with appropriate comparator therapy. An additional benefit cannot be derived, since the manufacturer has not submitted data suitable for any of the possible fields of application.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/diabetes_mellitus_typ_2_zusatznutzen_von_canagliflozin_ist_nicht_belegt.6132.html?&et_cid=4&et_lid=%208 [German]